Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,399 total articles
Kingstone Companies, Inc., a regional property and casualty insurance holding company, reported its best quarter ever for Q2 2026, with diluted EPS increasing 35% year-over-year to $1.05. Net premiums earned rose by 31%, driven by strong growth in direct premiums written and robust New York personal lines results. The company improved its GAAP net …
Vaalco Energy, Inc. announced a quarterly cash dividend of $0.0625 per share for Q3 2026, payable on September 22, 2026. This marks the company's 19th consecutive quarterly dividend, reflecting strong cash generation and a commitment to shareholder returns alongside ongoing capital investments in its diversified energy asset portfolio across Africa…
HCI Group, Inc. reported a robust second quarter 2026 with pre-tax income rising to $111 million from $94 million a year earlier and diluted EPS increasing to $5.60 from $5.18. The company grew gross premiums earned by 6% driven by higher policy volume, improved net investment income, and higher other revenues through their Exzeo insurance technolo…
Ryman Hospitality Properties, Inc. (NYSE: RHP) reported its financial results for Q2 2026, delivering all-time quarterly record consolidated revenue of $749 million and adjusted EBITDAre of $258.3 million. The Hospitality segment saw record same-store revenue driven by a premium group customer strategy and increased average daily rates, while the E…
X4 Pharmaceuticals reported Q2 2026 financial results highlighting operational improvements in their Phase 3 4WARD trial for chronic neutropenia, with enrollment underway across 110+ global sites. The company secured European Commission marketing authorization for XOLREMDI® (mavorixafor), the first treatment for WHIM syndrome in the EU, partnering …
Microchip Technology Incorporated announced fiscal Q1 2027 results with net sales of $1.485 billion, a 38% increase year-over-year and above guidance. Both GAAP and non-GAAP profits saw significant improvements, with GAAP EPS of $0.37 and non-GAAP EPS of $0.76 per diluted share. The company strengthened operational metrics including reduced invento…
Clarus Corporation, a leader in outdoor equipment, reported its second quarter 2026 financial results showing a 1.6% increase in sales to $56.2 million and a return to net income of $4.7 million compared to a net loss in the prior year. The Outdoor segment grew by 8.5%, driven by better inventory focus and product mix, while the Adventure segment d…
The E.W. Scripps Company reported Q2 2026 revenue of $490 million, a 9.2% decline year-over-year. The company recorded a substantial non-cash goodwill and intangible asset impairment charge of $1.1 billion attributed to challenges in its national advertising market and shifting audience measurement dynamics, resulting in a net loss of $1.2 billion …
LiqTech International, a clean technology firm specializing in advanced filtration systems, will release its second quarter 2026 financial results on August 12, 2026, before market open. A conference call and webcast will follow to discuss the results.
Super League, a Nasdaq-listed company specializing in audience intelligence and media activation for the global gaming population, will release its Q2 2026 financial results on August 14, 2026, accompanied by a live webinar to discuss the results.
KULR Technology Group, a NYSE American-listed company specializing in high-power energy systems for AI and mission-critical applications, announced its Q2 2026 earnings call on August 13, 2026. The company will release its financial results prior to the call and provide details for investors to participate.
CytomX Therapeutics announced its Q2 2026 financial results and provided updates on its clinical pipeline, focusing on Varsetatug masetecan (Varseta-M) for colorectal cancer with Phase 1 data expected by the end of 2026 and planned registrational studies in 2027. Expansion into other GI cancers and combination studies are underway. The company also…
Valhi, Inc. reported net income of $22.3 million ($0.78 per share) in Q2 2026, a significant increase from $0.9 million ($0.03 per share) in Q2 2025. The company's Chemicals segment showed strong sales and operating income growth due to market share gains, cost reductions, and strategic price increases. The Component Products segment also experienc…
ESCO Technologies Inc. announced a strong third quarter fiscal 2026 performance, highlighting a 14% increase in sales to $339 million, a 38% increase in adjusted EPS to $2.20, and record backlog of $1.54 billion. The company raised its full-year sales guidance to $1.30-$1.33 billion and adjusted EPS guidance to $8.30-$8.40, signaling robust growth …
Cognition Therapeutics reported Q2 2026 financial results highlighting progress in their Phase 3 clinical trial planning for zervimesine (CT1812), a treatment for dementia with Lewy bodies (DLB) psychosis. They received FDA feedback clarifying trial design, secured a patent allowance extending intellectual property protection through 2045, and exte…
Alta Equipment Group Inc. reported its second quarter 2026 financial results, showing sequential revenue growth across all segments despite a slight year-over-year revenue decline. The company improved new and used equipment sales gross margins, service gross profit percentages, and reduced interest expenses. Adjusted EBITDA remained stable year-ov…
Valhi, Inc., operating in chemicals, component products, and real estate management, declared a regular quarterly dividend of $0.08 per share payable on September 24, 2026.
Starling Oncology, a value-based community oncology group listed on NASDAQ as STLN, announced solid financial results for Q2 2026 with a 34.6% revenue increase year-over-year to $161.3 million and adjusted EBITDA turning positive at $229 thousand. The company raised its full-year 2026 guidance for revenue to $650-$670 million and gross profit to $1…
Applied Optoelectronics, Inc. reported a strong second quarter 2026 with record revenue of $191.9 million, marking the fifth consecutive quarter of growth. The company returned to non-GAAP profitability with net income of $5.5 million and saw a doubling in volume for its 800G products. The outlook remains positive with expected revenue growth and e…
Nephros, Inc., a Nasdaq-listed water filtration technology company, announced record financial results for Q2 ended June 30, 2026. The company achieved a 36% increase in net revenue year-over-year to $6 million, driven by 27% growth in core programmatic revenue and substantial expansion in service offerings. Net income rose significantly to $1.2 mi…
iRhythm Holdings, Inc. announced the acquisition of VitalConnect, a wearable biosensor and ambulatory cardiac monitoring company, for approximately $287.5 million. The acquisition expands iRhythm's cardiac monitoring portfolio to include mobile cardiac telemetry and multi-vitals monitoring across ambulatory, inpatient, and hospital-to-home care set…
AMD announced the acquisition of Taalas, a Canadian AI inference silicon pioneer, aiming to bolster its AI roadmap with advanced inference performance and efficiency. The integration of Taalas' technology will complement AMD's existing AI hardware and software portfolio, enhancing system-level solutions for AI inference workloads across multiple ap…
CVRx, Inc. announced a 16% increase in total revenue for Q2 2026 compared to the prior year, driven primarily by U.S. sales growth and expanded active implanting centers. Despite revenue gains and improved reimbursement policies—including new Medicare Advantage coverage from Humana—the company updated its full-year outlook lower due to fewer sales …
Apyx Medical Corporation reported strong second quarter 2026 financial results with total revenue of $13.9 million, a 22% increase year-over-year, primarily driven by 28% growth in its Surgical Aesthetics segment. The company successfully launched the power liposuction handpiece for its AYON Body Contouring System and reaffirmed full-year revenue g…
Trevi Therapeutics reported Q2 2026 financial results and significant progress with its investigational therapy Haduvio (oral nalbuphine ER) targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company initiated its first Phase 3 trial and a Ph…
